Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Immunotherapies have shown considerable efficacy for the treatment of various cancers, but a multitude of patients remain unresponsive for various reasons, including poor homing of T cells into tumors. In this study, we investigated the roles of the leukotriene B4 receptor, BLT1, and CXCR3, the receptor for CXCL9, CXCL10, and CXCL11, under endogenous as well as vaccine-induced antitumor immune response in a syngeneic murine model of B16 melanoma. Significant accelerations in tumor growth and reduced survival were observed in both BLT1−/− and CXCR3−/− mice as compared with wild-type (WT) mice. Analysis of tumor-infiltrating leukocytes revealed significant reduction of CD8+ T cells in the tumors of BLT1−/− and CXCR3−/− mice as compared with WT tumors, despite their similar frequencies in the periphery. Adoptive transfer of WT but not BLT1−/− or CXCR3−/− CTLs significantly reduced tumor growth in Rag2−/− mice, a function attributed to reduced infiltration of knockout CTLs into tumors. Cotransfer experiments suggested that WT CTLs do not facilitate the infiltration of knockout CTLs to tumors. Anti–programmed cell death-1 (PD-1) treatment reduced the tumor growth rate in WT mice but not in BLT1−/−, CXCR3−/−, or BLT1−/−CXCR3−/− mice. The loss of efficacy correlated with failure of the knockout CTLs to infiltrate into tumors upon anti–PD-1 treatment, suggesting an obligate requirement for both BLT1 and CXCR3 in mediating anti–PD-1 based antitumor immune response. These results demonstrate a critical role for both BLT1 and CXCR3 in CTL migration to tumors and thus may be targeted to enhance efficacy of CTL-based immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 2×
“Oncogenic event also occurs due to mutations caused by reactive oxygen species and nitrogen intermediates (ROS and RNI) as well as superoxide and hydroxyl radicals produced as a result of inflammation [9].”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 2×
“Figure adapted from [18].”
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“DC based vaccines, for example, accomplishes step 1 by enhancing the antigen loading and maturation ability of the DCs [34].”
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“CCR4-CCL22 axis is shown to be crucial in Treg recruitment to tumors, enhancing VEGF levels followed by angiogenesis and also cancer metastasis [95, 96].”
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“Autologous T cells transduced to express CD19 CARs alongwith 4-1BB co-stimulatory molecule have shown considerable success with 50% of them achieving partial or complete remissions and T cells persisting beyond two years in patients with refractory and relapsed B cell chronic lymphocytic leukemia [73].”
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“39 cancer study, it was reported that VEGF expression was three folds more in tumors without T cells than with T cells [167].”
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“Also, immunogenic cell death induces release of various tumor antigens/neo-antigens that act as endogenous vaccines [21-26].”
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“Also, immunogenic cell death induces release of various tumor antigens/neo-antigens that act as endogenous vaccines [21-26].”
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866 · cited 1×
“Treg cells constitute a considerable portion of the tumor mileu and through the production of immune suppressive molecules like IL-10 and TGF-β are extremely potent in dampening the anti-tumor response [94].”
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680 · cited 1×
“Further insight on the role of PD-1 as an inhibitory receptor was gained from a chronic viral infection model [51, 52].”
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343 · cited 1×
“express CXCR4 chemokine receptor on tumor cells involved in metastasis [12].”
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · cited 1×
“Also, immunogenic cell death induces release of various tumor antigens/neo-antigens that act as endogenous vaccines [21-26].”
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · cited 4×
“The ACT procedure involves preconditioning the patient by temporary ablation of immune system or lymphodepletion through total body irradiation or chemotherapy for removal of regulatory T cells, competition for homeostatic cytokines like IL-7 and IL-15 involved in T cell survival and proliferation thereby enhancing th…”
InfluentialLlosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465 · cited 1×
“This rekindled the role of lymphocytes in antitumor immunity as demonstrated in spontaneously arising tumors as well as chemically induced tumors [13, 14].”
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376 · cited 2×
“CCR5 [97], CCR10 [98] and CXCR3 [99] are some of the other chemokine receptors shown to be involved in”
Qin, S., Rottman, J. B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A. E., Moser, B., & Mackay, C. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1422 · Cited by 1,359
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · cited 1×
“T cells are present in higher numbers in tumors that express chemokines like CXCL9, CXCL10, CCL2, CCL3, CCL4 and CCL5 [162].”
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078 · cited 1×
“Also the efficacy of immunotherapies to neo-antigens suggest the possibility that higher number of mutations correlate with enhanced response to immunotherapy [74].”
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063 · cited 1×
“MSI, typically diagnosed by variable length DNA microsatellites, are mutations arising due to epigenetic silencing of DNA mismatch repair genes [58].”
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
Ernst, P. B., & Gold, B. D. (2000) · Annual Review of Microbiology · doi:10.1146/annurev.micro.54.1.615 · Cited by 554
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533 · cited 2×
“The Reed–Sternberg cells of Hodgkin lymphoma produce CCL17 and CCL22, recruiting CCR4 T regulatory cells to tumor-causing immune suppression [156].”
Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512 · cited 5×
“The role of CXCR3 and the ligands CXCL9 and CXCL10 in antitumor immunity is well established (29, 34, 57, 58).”
InfluentialSelf-citationExploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466 · cited 1×
“80% response rates in some studies (7, 8).”
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1187 · Cited by 432
Xiao, Y., & Freeman, G. J. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1397 · Cited by 368
Vicari, A. P., & Caux, C. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00033-8 · Cited by 351
Chou, R. C., Kim, N. D., Sadik, C. D., Seung, E., Lan, Y., Byrne, M. H., Haribabu, B., Iwakura, Y., & Luster, A. D. (2010) · Immunity · doi:10.1016/j.immuni.2010.07.018 · Cited by 342 · cited 1×
“Previous studies have shown that chemoattractant receptors get internalized in cells when they reach the site of inflammation (47, 49).”
Self-citationUpdate on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7
Bäck, M., Powell, W. S., Dahlén, S., Drazen, J. M., Evans, J. F., Serhan, C. N., Shimizu, T., Yokomizo, T., & Rovati, G. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12665 · Cited by 217 · cited 1×
“Leukotriene B4 (5(S), 12(R)-dihydroxy-6, 14-cis-8, 10-trans-eicosatetraenoic acid, LTB4) is a potent lipid inflammatory mediator, a calcium ionophore, that causes adhesion and chemotactic movement in leukocytes and stimulates aggregation, enzyme release and superoxide generation in neutrophils [169, 170].”
Lavergne, E., Combadière, C., Iga, M., Boissonnas, A., Bonduelle, O., Maho, M., Debré, P., & Combadiere, B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3755 · Cited by 89 · cited 1×
“CCR5 was the first chemokine receptor that was shown to be an important regulator of CTL trafficking to tumors because its cognate ligand facilitated the infiltration of CTL into tumors [127].”
Gene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy
Gough, M., Crittenden, M., Thanarajasingam, U., Sanchez-Perez, L., Thompson, J., Jevremovic, D., & Vile, R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5766 · Cited by 60 · cited 2×
“Adenoviral gene transfer to induce CCL3 expression in B16-ova tumors in vivo increased the efficacy of adoptively transferred tumor-specific effector OT1 T cells expressing its cognate receptor CCR5 [93, 129].”
Cited by
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790
“The requirement for the CXCL9:CXCR3 axis for the therapeutic efficacy of these immunotherapeutic treatments is consistent with previous data indicating that CXCL9/CXCL10:CXCR3 interactions govern immune cell infiltration into tumors prior to therapy (47) and following chemotherapy (10, 48, 49), IL2 treatment (50, 51),…”
ResultKey chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
Vilgelm, A. E., & Richmond, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00333 · Cited by 379
Metadata
- Authors
- Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D., & Haribabu, B.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09-01
- Volume
- 197
- Issue
- 5
- Pages
- 2016-2026
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2343745213
- Cited by
- 157
- References
- 45
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.